Premium
Sustained‐release theophylline pharmacokinetics in the cat
Author(s) -
DYE J. A.,
McKIERNAN B. C.,
D.JONES S.,
NEFFDAVIS C. A.,
KORITZ G. D.
Publication year - 1989
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1989.tb00654.x
Subject(s) - theophylline , aminophylline , pharmacokinetics , chemistry , bioavailability , plasma concentration , bronchodilator , pharmacology , crossover study , absorption (acoustics) , medicine , materials science , biochemistry , alternative medicine , pathology , composite material , asthma , placebo
Theophylline was administered in a three‐way crossover design study to six cats intravenously (Aminophylline USP, Invenex Laboratories, Chagrin Falls, OH) and orally as two sustained‐release formulations (Slo‐bid Gyrocaps® (SB), William H. Rorer, Inc., Fort Washington, PA; Theo‐Dur® Tablets (TD), Key Pharmaceuticals, Miami, FL). Values were determined for mean residence time (SB = 19.4 ± 3.2 h; TD = 15.8 ± 4.8 h), mean absorption time (SB = 8.0 ± 2.3 h; TD = 4.8 ± 2.3 h), absolute bioavailability (SB = 82 ± 27%; TD = 76 ± 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h). After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 ± 3.4 μg/ml; TD = 14.3 ± 6.7 μg/ml). Slo‐bid® was predicted to provide the least peak: trough fluctuation in theophylline concentrations. Slo‐bid® and Theo‐Dur® appear to have pharmacokinetic characteristics which, if given once‐daily, would maintain plasma theophylline concentrations of 5–20 μg/ml in the cat.